iShares Genomics Immunology and Healthcare ETF
IDNA
75 hedge funds and large institutions have $46.2M invested in iShares Genomics Immunology and Healthcare ETF in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 7 closing their positions.
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
12% more funds holding
Funds holding: 67 → 75 (+8)
2.21% more ownership
Funds ownership: 27.7% → 29.91% (+2.2%)
1% less capital invested
Capital invested by funds: $46.7M → $46.2M (-$497K)
46% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.69M |
| 2 |
Jane Street
New York
|
+$1.53M |
| 3 |
WAP
Wealthcare Advisory Partners
West Chester,
Pennsylvania
|
+$1.13M |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.09M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$612K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$4.05M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$838K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$628K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$577K |
| 5 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$458K |
IDNA Hedge Fund Activity: Q4 2022 in Review
75 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q4 2022, worth a combined $46.2M — down 1.1% from $46.7M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new IDNA positions and 7 closed out — a net gain of 12 holders — while 13 added to existing stakes and 24 trimmed.
The largest buyer was Bank of America, adding an estimated $1.69M. The largest seller was Wharton Business Group, cutting an estimated $4.05M.
- 75 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q4 2022, up from 67 in Q3 2022.
- Funds reported $46.2M of iShares Genomics Immunology and Healthcare ETF stock for Q4 2022, down 1.1% quarter-over-quarter.
- 19 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q4 2022 and 7 closed out, a net change of +12 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q4 2022 was Bank of America, an estimated $1.69M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q4 2022 was Wharton Business Group, an estimated $4.05M sold.
Based on aggregated 13F filings for Q4 2022.